Health
V114 pneumococcal vaccine noninferior to PCV13 in adults, phase 3 studies show – Healio
Merck’s investigational V114 pneumococcal conjugate vaccine — which includes 15 serotypes — is noninferior to the 13-valent pneumococcal conju…
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected] to Healio
Merck’s investigational V114 pneumococcal conjugate vaccine — which includes 15 serotypes — is noninferior to the 13-valent pneumococcal conjugate vaccine currently on the market for adults, the company announced in a press release.
“Diseases caused by serotypes not covered by the currently available pneumococcal conjugate vaccine are in…
